80119-31-9

Upstream product

• 19432-95-2 3-(4-methylphenyl)sulfonyl-1-chloropropane 
• 330-91-6 bis-(4-fluoro-phenyl)-amine 
• 95017-62-2 3-chloro-N,N-bis(4-fluorophenyl)propanamide 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 371-40-4 4-fluoroaniline 
• 352-34-1 4-fluoro-1-iodobenzene 

Downstream Products

• 95017-61-1 2-(4-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-piperazin-1-yl)-ethanol 
• 95017-59-7 Bis-(4-fluoro-phenyl)-[3-(4-phenyl-piperazin-1-yl)-propyl]-amine 
• 80119-59-1 1-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-4-(4-chloro-phenyl)-piperidin-4-ol 
• 80119-57-9 1-<3-propyl>-4-piperidinone 
• 80119-34-2 1-<1-<3-propyl>-4-piperidinyl>-1,3-dihydro-2H-benzimidazol-2-one 
• 80119-53-5 1-(1-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-piperidin-4-yl)-5,6-dimethyl-1,3-dihydro-benzoimidazol-2-one 
• 97861-05-7 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(3-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 
• 97861-06-8 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(2-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 
• 97861-03-5 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(4-isopropyl-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 
• 97861-04-6 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(3-trifluoromethyl-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 
• 80120-14-5 8-<3-propyl>-1-phenyl-1,3,8-triazaspiro<4.5>decan-4-one 
• 97861-02-4 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-p-tolyl-1,3,8-triaza-spiro[4.5]decan-4-one 
• 80119-32-0 8-<3-propyl>-1-(4-fluorophenyl)-1,3,8-triazaspiro<4.5>decan-4-one 
• 97861-01-3 8-{3-[Bis-(4-fluoro-phenyl)-amino]-propyl}-1-(4-methoxy-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 

Relevant academic research and scientific papers

Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity

Several recent reports have highlighted the feasibility of the use of penfluridol, a well-known antipsychotic agent, as a chemotherapeutic agent. In vivo experiments have confirmed the cytotoxic activity of penfluridol in triple-negative breast cancer model, lung cancer model, and further studies have been proposed to assess its anticancer activity and viability for the treatment of glioblastomas. However, penfluridol anticancer activity was observed at a dosage significantly higher than that administered in antipsychotic therapy, thus raising the concern for the potential onset of CNS side effects in patients undergoing intensive pharmacological treatment. In this study, we evaluate the potential CNS toxicity of penfluridol side by side with a set of analogs.

1-piperidines and Related Compounds, Potential Antipsychotic Agents with Low Cataleptogenic Profiles

On the basis of a structural model of the postsynaptic dopaminergic antagonist pharmacophore, a series of 1-piperidines and related compounds was synthesized and evaluated for potential antipsychotic activity.For a rapid measure of activity, the target compounds were initially screened in vitro for inhibition of haloperidol binding and in vivo in a test of locomotor activity.Behavioral efficacy of compounds identified from the initial screens was more accurately measured in rats by using a suppression of high base-line medial forebrain bundle self-stimulation test model.The propensity of these compounds for causing extrapyramidal side effects was evaluated by using a rat catalepsy method.On the basis of these test models, we have shown that the methine carbon of the 1-(4,4-diarylbutyl)piperidines can be advantageously replaced with a nitrogen atom.The 1-piperidines were less cataleptic than the corresponding 1-(4,4-diarylbutyl)piperidines.The compounds with the widest separation between efficacious dose and cataleptic dose are 8-propyl>-1-phenyl-1,3,8-triazaspirodecan-4-one (6), 1-propyl>-4-piperidinyl>-1,3-dihydro-2H-benzimidazol-2-one (11), 1-propyl>-1,2,3,6-tetrahydro-4-pyridinyl>-1,3-dihydro-2H-benzimidazol-2-one (22), and 1-propyl>-4-(2-methoxyphenyl)piperazine (26).